Johnathan Whetstine was named program leader of the Cancer Epigenetics Program at Fox Chase Cancer Center.
Whetstine comes to Fox Chase from Massachusetts General Hospital Cancer Center and Harvard Medical School, where he served as vice chair of the Epigenetics Program. He also held appointments as associate geneticist and associate professor in the department of medicine.
Whetstine’s work has focused on understanding tumor heterogeneity and drug response. He holds the scholar award from the Leukemia & Lymphoma Society and an NIH R01 grant, as well as funding from the American Lung Association, Alex Lemonade Stand Foundation and AstraZeneca.
The new Cancer Epigenetics Program Whetstine will lead has basic, translational, and clinical research components.
Whetstine will begin his work at Fox Chase on Dec. 1.
